Intra-arterial Mannitol

Phase 1Small molecule

NNorthwell Health

Intra-arterial Mannitol is one of 57 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

GlioblastomaActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Zinecard

CChildren's Oncology Group

Preclinical

2 3

Chirocaine

PPurdue Pharma LP

Preclinical

1 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Preclinical

—6

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 7

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 8

Intra-arterial Mannitol

NNorthwell Health

Phase 1

1 9

Ablavar

LLantheus Medical Imaging

Preclinical

2 10

Gadolinium-Chelate

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Relapsed/refractory

NCT02800486

Q4 2027

Phase 1/2Recruiting

Glioblastoma

NCT02861898

Clinical

Trials by Indication[1]

Relapsed/Refractory1 trial

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Recruiting·NNorthwell Health·Phase 2·NCT02800486·37 enrolled

Breast Cancer1 trial

Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

Terminated·NNorthwell Health·Phase 1·NCT02571530·2 enrolled

Glioblastoma1 trial

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Recruiting·NNorthwell Health·Phase 1/2·NCT02861898·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Intra-arterial Mannitol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intra-arterial Mannitol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intra-arterial Mannitol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwell Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNorthwell Health

Intra-arterial Mannitol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Relapsed/Refractory1 trial

Breast Cancer1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News